

Stepping Forward to Transform Mantle Cell Lymphoma (MCL) Management: Guidance on the Selection and Use of BTK Inhibitors (BTKi)

Faculty Affiliations and Disclosures

Chair and Moderator

Pier Luigi Zinzani, MD, PhD
Institute of Hematology
“Seragnoli”
University of Bologna
Bologna, Italy

Pier Luigi Zinzani, MD, PhD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie; BeiGene; Bristol Myers Squibb; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly; Merck; Novartis; Recordati; Regeneron; Roche; SOBI; Takeda
Speaker for AbbVie; BeiGene; Bristol Myers Squibb; Incyte; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly; Merck; Novartis; Recordati; Regeneron; Roche; SOBI; Takeda

Faculty and Presenter

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Hematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.

Grant/Research Support from AstraZeneca and BeiGene.

Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.

Faculty and Presenter

Christine Ryan, MD
Instructor in Medicine, Harvard Medical School
Leader, Mantle Cell Lymphoma, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts, US

Disclosure is pending.

